Trevi Therapeutics (TRVI) Accounts Payables (2018 - 2026)

Trevi Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 55.88% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 55.88% YoY), while the FY2025 annual figure was $3.9 million, up 14.56% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.2 million, down from $3.9 million in the prior quarter.
• The five-year high for Accounts Payables was $3.9 million in Q2 2022, with the low at $1.3 million in Q3 2023.
• The 5-year median for Accounts Payables is $2.1 million (2024), against an average of $2.3 million.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables jumped 116.98% in 2022, then tumbled 65.67% in 2023.
• Trevi Therapeutics' Accounts Payables stood at $2.9 million in 2022, then sank by 36.68% to $1.8 million in 2023, then soared by 88.72% to $3.4 million in 2024, then gained by 14.56% to $3.9 million in 2025, then tumbled by 43.36% to $2.2 million in 2026.
• Business Quant data shows TRVI's Accounts Payables at $2.2 million in Q1 2026, $3.9 million in Q4 2025, and $2.7 million in Q3 2025.